The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients

Nancy F. Crum-Cianflone, Katherine Huppler Hullsiek, Vincent Marconi, Amy Weintrob, Anuradha Ganesan, R. Vincent Barthel, Susan Fraser, Mollie Poehlman Roediger, Brian Agan, Scott Wegner

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

BACKGROUND: Preclinical studies suggest that the antiretroviral agent, nelfinavir mesylate (NFV), may have antineoplastic properties. The relationship between NFV and cancer incidence among HIV-infected patients is unknown. METHODS: We evaluated the impact of NFV on cancer development in a large cohort of HIV-infected persons with 108 cancer events during 13,421 person-years of follow-up. Using multivariate time-updated Cox proportional hazard models, the risk of cancer among those receiving NFV were compared to those on non-NFV antiretroviral regimens. RESULTS: The risk of cancer among those receiving NFV was similar to those on non-NFV antiretroviral regimens (hazard ratio 1.0, 95% confidence interval 0.5, 1.7, P = 0.90). We also examined AIDS-defining and non-AIDS-defining cancers separately and found no significant associations between NFV use and cancer risk. Antiretroviral use, with or without a protease inhibitor (PI) component, was associated with a reduced risk of AIDS-defining cancers compared with no antiretroviral therapy; however, the risk of cancer was the same among those using PI or PI-sparing regimens. DISCUSSION: Despite reports that NFV may have tumoricidal activity, we found no significant relationship between NFV or PI use compared with other antiretrovirals and the risk of developing cancer among a large cohort of HIV-infected persons.

Original languageEnglish (US)
Pages (from-to)305-309
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes
Volume51
Issue number3
DOIs
StatePublished - Jul 2009
Externally publishedYes

Keywords

  • Cancers
  • HIV
  • Nelfinavir
  • Protease inhibitor

Fingerprint Dive into the research topics of 'The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients'. Together they form a unique fingerprint.

Cite this